Document Detail


Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases.
MedLine Citation:
PMID:  19649366     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To estimate the impact of global strategies, such as pooled procurement arrangements, third-party price negotiation and differential pricing, on reducing the price of antiretrovirals (ARVs), which currently hinders universal access to HIV/AIDS treatment. METHODS: We estimated the impact of global strategies to reduce ARV prices using data on 7253 procurement transactions (July 2002-October 2007) from databases hosted by WHO and the Global Fund to Fight AIDS, Tuberculosis and Malaria. FINDINGS: For 19 of 24 ARV dosage forms, we detected no association between price and volume purchased. For the other five ARVs, high-volume purchases were 4-21% less expensive than medium- or low-volume purchases. Nine of 13 generic ARVs were priced 6-36% lower when purchased under the Clinton Foundation HIV/AIDS Initiative (CHAI). Fifteen of 18 branded ARVs were priced 23-498% higher for differentially priced purchases compared with non-CHAI generic purchases. However, two branded, differentially priced ARVs were priced 63% and 73% lower, respectively, than generic non-CHAI equivalents. CONCLUSION: Large purchase volumes did not necessarily result in lower ARV prices. Although current plans for pooled procurement will further increase purchase volumes, savings are uncertain and should be balanced against programmatic costs. Third-party negotiation by CHAI resulted in lower generic ARV prices. Generics were less expensive than differentially priced branded ARVs, except where little generic competition exists. Alternative strategies for reducing ARV prices, such as streamlining financial management systems, improving demand forecasting and removing barriers to generics, should be explored.
Authors:
Brenda Waning; Warren Kaplan; Alexis C King; Danielle A Lawrence; Hubert G Leufkens; Matthew P Fox
Related Documents :
11598966 - Why biologists should support the exploration of mars.
6503306 - Coordination: a vector-matrix description of transformations of overcomplete cns coordi...
21059696 - Barriers to implementing screening and brief interventions in general practice: finding...
613206 - The laboratory report: a problem in communication between clinician and microbiologist?
953936 - Management of the rape victim.
1994196 - Ear disease in three aboriginal communities in western australia.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Bulletin of the World Health Organization     Volume:  87     ISSN:  1564-0604     ISO Abbreviation:  Bull. World Health Organ.     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-08-03     Completed Date:  2009-11-17     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  7507052     Medline TA:  Bull World Health Organ     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  520-8     Citation Subset:  IM    
Affiliation:
Boston University School of Medicine, Boston, MA 02118, United States of America. bwaning@bu.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Retroviral Agents / economics*
Commerce / economics,  trends*
Cost Control*
Databases, Factual
Drug Costs / trends
HIV Infections / drug therapy
Humans
Negotiating
World Health*
Chemical
Reg. No./Substance:
0/Anti-Retroviral Agents
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Diabetes treatment and control: the effect of public health insurance for the poor in Mexico.
Next Document:  Evidence base for pre-employment medical screening.